Some of you may have seen the headlines this week about JDRF and Amylin investigating a new diabetes treatment — essentially a mixture of insulin and pramlintide (brand name Symlin), two substances that are only FDA approved for entirely separate use at the moment. Interesting!
The reasoning seems highly practical: “A co-formulated therapy that harnesses the benefit of both hormones might better mimic the natural physiology of the pancreas and simplify dosing decisions.”
Also in…
Read more »
By
WilD on
April 30, 2011
Our controversial columnist Wil Dubois is back with another spicy edition of our new diabetes advice column, Ask D’Mine.
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
You know the answers you get here will be brutally honest and interesting, to say the least.
Robyn from Colorado, type 1, writes: I have traveled a lot over the years with my insulin in tow. Upon completion of each trip I always come to the…
Read more »
The new contact form we launched here recently to make it easier for people to share their thoughts and contribute ideas is bringing in some very interesting stuff. One note that caught our attention was a query from a woman named Sarah:
“I was diagnosed with type 2 diabetes in 2001. I currently am well-controlled on oral medication, but I am also fat (not, I’m sure you will agree, an unusual situation). When my endo says…
Read more »
By
AmyT on
August 23, 2010
My Spring post on the new injectable type 2 diabetes drug Victoza is in the running for one of the most-commented-ever blog posts here at the ‘Mine. Over 100 people now taking the medication have chimed in.
Victoza, for the unfamiliar, is a new once-daily form of the new-generation GLP-1 drugs that stimulate pancreas cells to release insulin in people with type 2 diabetes. It’s a head-to-head competitor with the injectable drug Byetta, and both…
Read more »
